Jacob P. Thyssen
YOU?
Author Swipe
View article: Baseline characteristics of atopic eczema patients enrolled in seven European registries united in the <scp>TREatment</scp> of <scp>ATopic</scp> eczema ( <scp>TREAT</scp> ) registry taskforce
Baseline characteristics of atopic eczema patients enrolled in seven European registries united in the <span>TREatment</span> of <span>ATopic</span> eczema ( <span>TREAT</span> ) registry taskforce Open
Background The TREAT Registry Taskforce is a collaborative effort of international registries aiming to provide real‐world data on the long‐term efficacy, cost‐effectiveness and safety of systemic treatments and phototherapy for atopic ecz…
View article: Impact of Long-term Stability on Mental Health in Adults with Atopic Dermatitis: A Cohort Study with Unsupervised Cluster Analysis
Impact of Long-term Stability on Mental Health in Adults with Atopic Dermatitis: A Cohort Study with Unsupervised Cluster Analysis Open
Atopic dermatitis (AD) is a heterogeneous disease characterized by unpredictable flares, potentially leading to impaired mental health. Adult patients with a dermatologist-verified AD diagnosis received after their 18th birthday were group…
View article: Gene–Environment Interaction Affects Risk of Atopic Eczema: Population and In Vitro Studies
Gene–Environment Interaction Affects Risk of Atopic Eczema: Population and In Vitro Studies Open
Background Multiple environmental and genetic factors play a role in the pathogenesis of atopic eczema ( AE ). We aimed to investigate gene–environment interactions (G × E) to improve understanding of the pathophysiology. Methods We analys…
View article: Unique dermal bacterial signature differentiates atopic dermatitis skin from healthy
Unique dermal bacterial signature differentiates atopic dermatitis skin from healthy Open
Gaining a deeper understanding of the variation in skin microbiota across habitats and layers provides critical insights into the complex host-microbial interactions that drive inflammatory skin diseases. Our study investigated dermal vers…
View article: Health-Related Quality of Life in Chronic Hand Eczema in a Phase 2b Trial of Delgocitinib Cream
Health-Related Quality of Life in Chronic Hand Eczema in a Phase 2b Trial of Delgocitinib Cream Open
ClinicalTrials. gov identifier NCT03683719.
View article: Chronic Hand Eczema, Real World, and Patient Centricity: A Narrative Review
Chronic Hand Eczema, Real World, and Patient Centricity: A Narrative Review Open
Chronic hand eczema is a multifactorial, fluctuating, inflammatory skin disease of the hands and wrists, defined as hand eczema that persists for at least 3 months or recurs at least twice within 1 year. Chronic hand eczema is heterogeneou…
View article: Long-Term Disease Control and Minimal Disease Activity of Head and Neck Atopic Dermatitis in Patients Treated with Tralokinumab up to 4 Years
Long-Term Disease Control and Minimal Disease Activity of Head and Neck Atopic Dermatitis in Patients Treated with Tralokinumab up to 4 Years Open
NCT03131648 (ECZTRA 1); study start date: 30 May, 2017; primary completion date: 7 August, 2018; study completion date: 10 October, 2019. NCT03160885 (ECZTRA 2); study start date: 12 June, 2017; primary completion date: 4 September, 2019; …
View article: Counselling Needs in Atopic Dermatitis: Perspectives on Pregnancy and Treatment
Counselling Needs in Atopic Dermatitis: Perspectives on Pregnancy and Treatment Open
Atopic dermatitis (AD) is a common inflammatory skin disease affecting 5–8% of adults, with many being of reproductive age and potentially experiencing AD- and treatment-related challenges during family planning and pregnancy (FPP). This s…
View article: The Prevalence and Severity of Hand Eczema Among Adults in Tasiilaq, East Greenland
The Prevalence and Severity of Hand Eczema Among Adults in Tasiilaq, East Greenland Open
Background Hand eczema (HE) is described as a common disease in Greenland, but studies on its epidemiology and severity are lacking. Objectives To investigate the point prevalence and severity of HE among adults in East Greenland in relati…
View article: Real-world Drug Survival of Biosimilar SB5 vs GP2017 Following a Mandatory Non-medical Switch from Adalimumab Originator for Psoriasis: A Nationwide Cohort Study
Real-world Drug Survival of Biosimilar SB5 vs GP2017 Following a Mandatory Non-medical Switch from Adalimumab Originator for Psoriasis: A Nationwide Cohort Study Open
Biosimilars are designed to be analogous to the biologic originators. However, comprehensive comparisons between biosimilars are limited and lacking for patients with psoriasis. This study’s objective was to compare 1-year drug survival of…
View article: Sex Disparities of Health-related Quality of Life in Moderate to Severe Psoriasis: A Real-world Analysis from the Swiss Psoriasis Registry (SDNTT)
Sex Disparities of Health-related Quality of Life in Moderate to Severe Psoriasis: A Real-world Analysis from the Swiss Psoriasis Registry (SDNTT) Open
Real-world data on gender differences in quality of life among psoriasis patients before and during treatment are scarce. This study analysed data of 748 adults with moderate-to-severe psoriasis enrolled in the Swiss Dermatology Network of…
View article: Transcriptomic profiling of chronic hand eczema skin reveals shared immune pathways and molecular drivers across subtypes
Transcriptomic profiling of chronic hand eczema skin reveals shared immune pathways and molecular drivers across subtypes Open
The lesional CHE transcriptome is primarily shared among subtypes and is characterized by activation of several immune pathways, dominated by TH1 and TH2. Key shared upstream regulators were identified, highlighting potential universal the…
View article: EXtending Omalizumab Treatment Intervals in patients with Chronic spontaneous urticaria (EXOTIC): protocol of a multicentre, randomised, open-label, non-inferiority trial
EXtending Omalizumab Treatment Intervals in patients with Chronic spontaneous urticaria (EXOTIC): protocol of a multicentre, randomised, open-label, non-inferiority trial Open
Introduction Omalizumab, an anti-IgE monoclonal antibody, is effective in treating antihistamine-refractory chronic spontaneous urticaria (CSU). However, tapering strategies for omalizumab are currently not well-studied, and patients may b…
View article: Pre-asthma: a useful concept? A EUFOREA paper. Part 2—late onset eosinophilic asthma
Pre-asthma: a useful concept? A EUFOREA paper. Part 2—late onset eosinophilic asthma Open
The concept of pre-diabetes has led to provision of measures to reduce disease progression through identification of subjects at risk of diabetes. We previously considered the idea of pre-asthma in relation to allergic asthma and considere…
View article: IL-9 sensitizes human TH2 cells to proinflammatory IL-18 signals in atopic dermatitis
IL-9 sensitizes human TH2 cells to proinflammatory IL-18 signals in atopic dermatitis Open
Our data identify a novel IL-9/IL-18 axis that contributes to TH2 responses in AD. Our findings suggest that both IL-9 and IL-18 could represent upstream targets for future treatment of AD.
View article: Efficacy and Safety of Upadacitinib versus Dupilumab Treatment for Moderate-to-Severe Atopic Dermatitis in Four Body Regions: Analysis from the Heads Up Study
Efficacy and Safety of Upadacitinib versus Dupilumab Treatment for Moderate-to-Severe Atopic Dermatitis in Four Body Regions: Analysis from the Heads Up Study Open
Introduction: Upadacitinib has demonstrated high and rapid rates of efficacy in adolescent and adult patients with moderate-to-severe atopic dermatitis (AD) as assessed by the Eczema Area and Severity Index (EASI). This post hoc analysis a…
View article: Skin diseases among adults in Tasiilaq, East Greenland
Skin diseases among adults in Tasiilaq, East Greenland Open
Cold climate and unique genetic and environmental factors may influence the prevalence of skin diseases in Greenland. However, there is a lack of epidemiological studies on skin diseases in the adult Greenlandic population. To address this…
View article: A practical guide to using oral Janus kinase inhibitors for atopic dermatitis from the International Eczema Council
A practical guide to using oral Janus kinase inhibitors for atopic dermatitis from the International Eczema Council Open
Background Janus kinase inhibitors (JAKi) have the potential to alter the landscape of atopic dermatitis (AD) management dramatically, owing to promising efficacy results from phase III trials and their rapid onset of action. However, JAKi…
View article: Risk factors that limit use of oral JAK inhibitors in chronic hand eczema: Findings from the Danish Skin Cohort
Risk factors that limit use of oral JAK inhibitors in chronic hand eczema: Findings from the Danish Skin Cohort Open
Most CHE patients have risk factors limiting appropriateness of oral JAKi use. Health care providers should assess risk factors in their patients when choosing treatment for CHE.